Kwan-Lung Ko

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Prognostic Factors

Patients With Inflammatory Bowel Disease

Ejection Fraction

Top Venues

Alimentary pharmacology & therapeutics

Journal of viral hepatitis

This page only lists publications with an associated author ORCID identifier.

Publications

Kwan-Lung Ko, Ivan Fan-Ngai Hung, Wai-Keung Leung
Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game. Authors' reply. Alimentary pharmacology & therapeutics 56 (2) (2022)
Kwan-Lung Ko, Yuk-Fai Lam, Ka-Shing Cheung, Ivan Fan-Ngai Hung, Wai-Keung Leung
Clinical trial: intra dermal hepatitis B vaccination with topical imiquimod versus intra muscular hepatitis B vaccination in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 56 (2) (2022)
Loey Lung-Yi Mak, Kwan-Lung Ko, Elvis Wai-Pan To, Danny Ka-Ho Wong, Wai Kay Seto, James Fung, Man Fung Yuen
Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. Gut and liver 14 (5) (2021)
Kwan-Lung Ko, Lung-Yi Mak, Ka-Shing Cheung, Man-Fung Yuen
Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Research 9 (2020)
Kwan-Lung Ko, Wai-Pan To, Loey Lung-Yi Mak, Wai Kay Seto, Qin Ning, James Fung, Ching-Lung Lai, Man Fung Yuen
A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. Journal of viral hepatitis 27 (4) (2019)